Brief: Alphamab Oncology Says Its Combination Therapy Achieved Preliminary Positive Results
10/11/2020 06:59
Nov 10 (Reuters) - Alphamab Oncology 9966.HK :
* COMBINATION THERAPY OF KN026, KN046 ACHIEVED PRELIMINARY
POSITIVE RESULTS IN PHASE IB TRIAL
Source text for Eikon: ID:nHKS8M8ZQP
Further company coverage: 9966.HK
(Reporting by Yamini C S)
((Yamini.CS@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)